Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Prognostic Significance of Immunocytometric Count of Medullar Blasts in Myelodysplastic Syndromes

Alfredo Molteni, Valentina Speziale, Marta Riva, Michele Nichelatti, Rosa Greco, Clara Cesana, Barbara Scarpati, Enrica Morra, MD

Blood (2012) 120 (21): 4945.

https://doi.org/10.1182/blood.V120.21.4945.4945

Published: 2012

Journal Articles

Microarray Gene Expression Signature Indicates ARSD As a New Marker Associated with Igvh Mutational Status, ZAP-70 and Disease Progression in CLL,

Alessandra Trojani, Barbara Di Camillo, Alessandra Tedeschi, Lodola Milena, Simona Montesano, Francesca Ricci, Eleonora Vismara, Antonino Greco, Silvio Veronese, Anna Colosimo, Barbara Scarpati, Aldo Orlacchio, Sabata Martino, Chiara Colombo, Maria Angela Mura, Michele Nichelatti, Marco Montillo, Enrica Morra

Blood (2011) 118 (21): 3447.

https://doi.org/10.1182/blood.V118.21.3447.3447

Published: 2011

Journal Articles

Zap-70 EXPRESSION and Igvh Mutational Status as Markers for Gene EXPRESSION Signature IN B-CLL PATIENTS for Prognostic Classification.

Alessandra Trojani, Barbara Di Camillo, Alessandra Tedeschi, Milena Lodola, Chiara Colombo, Francesca Ricci, Silvio Veronese, Barbara Scarpati, Enrica Morra, Marco Montillo

Blood (2009) 114 (22): 4388.

https://doi.org/10.1182/blood.V114.22.4388.4388

Published: 2009

Journal Articles

Clinical Follow-up Demonstrates Differential Accuracy of Flow Cytometry and Cytomorphology for the Detection of Hematologic Malignancy in Hypercellular Body Cavity Fluids.

Clara Cesana, Catherine Klersy, Barbara Scarpati, Bruno Brando, Elisabetta Volpato, Giambattista Bertani, Maurizio Faleri, Annamaria Nosari, Silvia Cantoni, Ursula Ferri, Linda Scampini, Claudia Barba, Giuliana Lando, Enrica Morra, Roberto Cairoli

Blood (2009) 114 (22): 5018.

https://doi.org/10.1182/blood.V114.22.5018.5018

Published: 2009

Journal Articles

Flow Cytometric Examination of Non-Hematic Body Fluids in Hematologic Malignancies: A Comparison with Cytology.

Clara Cesana, MD, Barbara Scarpati, Bruno Brando, MD, Claudia Barba, Ursula Ferri, Linda Scampini, Pierluigi Oreste, MD, Silvio Veronese, Annamaria Nosari, MD, Enrica Morra, MD, Roberto Cairoli, MD

Blood (2007) 110 (11): 4237.

https://doi.org/10.1182/blood.V110.11.4237.4237

Published: 2007

Journal Articles

Prognostic Significance of CD33, CD34 and CD117 Expression on Bone Marrow Blasts of Patients with Myelodysplastic Syndromes.

Guido Nador, Alfredo Molteni, Clara Cesana, Michele Nichelatti, Barbara Scarpati, Roberto Cairoli, Luciana Barbarano, Annamaria Nosari, Enrica Morra

Blood (2007) 110 (11): 4604.

https://doi.org/10.1182/blood.V110.11.4604.4604

Published: 2007

Journal Articles

Pharmacokinetic Analysis of Subcutaneous Alemtuzumab as Consolidation Therapy To Achieve MRD-Negative Responses.

Mario Regazzi, Michela Montagna, Antonia Avanzini, Barbara Scarpati, Anna Colosimo, Silvio Veronese, Alessandra Tedeschi, Sara Miqueleiz, Francesca Ricci, Liliana Intropido, Enrica Morra, Marco Montillo

Blood (2005) 106 (11): 2962.

https://doi.org/10.1182/blood.V106.11.2962.2962

Published: 2005

Journal Articles

Purging "In Vivo" with Alemtuzumab (Campath-1H) before Autologous Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).

Marco Montillo, Alessandra Tedeschi, Roberto Cairoli, Sara Miqueleiz, Barbara Scarpati, Anna Maria Cafro, Liliana Intropido, Renata Farioli, Silvio Veronese, Enrica Morra

Blood (2005) 106 (11): 2927.

https://doi.org/10.1182/blood.V106.11.2927.2927

Published: 2005

Journal Articles

Combination of Fludarabine (FAMP) Cyclophosphamide (CTX) and Alemtuzumab for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Alessandra Tedeschi, Marco Montillo, Sara Miqueleiz, Michela Draisci, Francesca Ricci, Barbara Scarpati, Mariangela Mura, Monica Crugnola, Enrica Morra

Blood (2005) 106 (11): 5036.

https://doi.org/10.1182/blood.V106.11.5036.5036

Published: 2005

Journal Articles

Alemtuzumab as Consolidation after a Response to Fludarabine Is Effective To Purge Residual Disease in Patients with Chronic Lymphocytic Leukemia.

Marco Montillo, MD, Alessandra Tedeschi, MD, Valentina Rossi, MD, Anna Maria Cafro, MD, Roberto Cairoli, MD, Silvio Veronese, PhD, Barbara Scarpati, PhD, Renata Farioli, PhD, Mario Regazzi, MD, Marcello Gambacorta, MD, Enrica Morra, MD

Blood (2004) 104 (11): 479.

https://doi.org/10.1182/blood.V104.11.479.479

Published: 2004

NARROW

Prognostic Significance of Immunocytometric Count of Medullar Blasts in Myelodysplastic Syndromes

Microarray Gene Expression Signature Indicates ARSD As a New Marker Associated with Igvh Mutational Status, ZAP-70 and Disease Progression in CLL,

Zap-70 EXPRESSION and Igvh Mutational Status as Markers for Gene EXPRESSION Signature IN B-CLL PATIENTS for Prognostic Classification.

Clinical Follow-up Demonstrates Differential Accuracy of Flow Cytometry and Cytomorphology for the Detection of Hematologic Malignancy in Hypercellular Body Cavity Fluids.

Flow Cytometric Examination of Non-Hematic Body Fluids in Hematologic Malignancies: A Comparison with Cytology.

Prognostic Significance of CD33, CD34 and CD117 Expression on Bone Marrow Blasts of Patients with Myelodysplastic Syndromes.

Pharmacokinetic Analysis of Subcutaneous Alemtuzumab as Consolidation Therapy To Achieve MRD-Negative Responses.

Purging "In Vivo" with Alemtuzumab (Campath-1H) before Autologous Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).

Combination of Fludarabine (FAMP) Cyclophosphamide (CTX) and Alemtuzumab for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Alemtuzumab as Consolidation after a Response to Fludarabine Is Effective To Purge Residual Disease in Patients with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only